BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 18336279)

  • 1. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-hsd1 inhibitors.
    Saiah E
    Curr Med Chem; 2008; 15(7):642-9. PubMed ID: 18336279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
    Atanasov AG; Odermatt A
    Endocr Metab Immune Disord Drug Targets; 2007 Jun; 7(2):125-40. PubMed ID: 17584152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
    Oppermann U
    Endocr Metab Immune Disord Drug Targets; 2006 Sep; 6(3):259-69. PubMed ID: 17017977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M
    Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
    Ge R; Huang Y; Liang G; Li X
    Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the discovery of 11beta-HSD1 inhibitors.
    Boyle CD
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
    Masuzaki H; Flier JS
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in 11β-HSD1 inhibitors for the treatment of metabolic diseases: A comprehensive guide to their chemical structure diversity in drug development.
    Chuanxin Z; Shengzheng W; Lei D; Duoli X; Jin L; Fuzeng R; Aiping L; Ge Z
    Eur J Med Chem; 2020 Apr; 191():112134. PubMed ID: 32088493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1.
    Su X; Pradaux-Caggiano F; Vicker N; Thomas MP; Halem H; Culler MD; Potter BV
    ChemMedChem; 2011 Sep; 6(9):1616-29. PubMed ID: 21714097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M; Seckl JR
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
    Tomlinson JW
    Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
    Sun D; Wang M; Wang Z
    Curr Top Med Chem; 2011; 11(12):1464-75. PubMed ID: 21510838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations.
    Odermatt A; Nashev LG
    J Steroid Biochem Mol Biol; 2010 Mar; 119(1-2):1-13. PubMed ID: 20100573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of ELISA Technique and Human Microsomes in the Search for 11
    Kupczyk D; Studzińska R; Bilski R; Woźniak A
    Biomed Res Int; 2019; 2019():5747436. PubMed ID: 31214617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome.
    Loerz C; Maser E
    J Steroid Biochem Mol Biol; 2017 Nov; 174():65-71. PubMed ID: 28765040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzofuran derivatives inhibit 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose tissue.
    Kiyonaga D; Tagawa N; Yamaguchi Y; Wakabayashi M; Kogure T; Ueda M; Miyata O; Kobayashi Y
    Biol Pharm Bull; 2012; 35(8):1275-80. PubMed ID: 22863925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.